The effectiveness of an asthma control questionnaire (ACQ) in predicting clinical decisions in an inhaled corticosteroid tapering protocol

2002 ◽  
Vol 109 (1) ◽  
pp. S293-S293
Author(s):  
Fred White ◽  
Harold Kim ◽  
Elizabeth F Juniper ◽  
Ute Repple ◽  
Mark Gibson ◽  
...  
Keyword(s):  
Asthma Control ◽  
Clinical Decisions ◽  
Inhaled Corticosteroid ◽  
Asthma Control Questionnaire

Lessons learned from clinical trials of asthma

2019 ◽  
Vol 40 (6) ◽  
pp. 410-413
Author(s):  
Paul A. Greenberger
Keyword(s):  
Asthma Control ◽  
Severe Asthma ◽  
Immunoglobulin E ◽  
Environmental Control ◽  
Mild Asthma ◽  
Inhaled Corticosteroid ◽  
Biologic Therapies ◽  
Asthma Control Questionnaire ◽  
Exacerbation Rate ◽  
Sputum Eosinophilia

Exacerbations of persistent or intermittent asthma should be anticipated by physicians and health-care professionals. Patients who are likely to experience an exacerbation often have a history of an exacerbation in the previous year, and the absolute eosinophil count in peripheral blood is ≥ 400/μL. Similarly, expectorated or induced sputum eosinophilia of ≥2% is associated with exacerbations. These phenotypic findings have led to effective biologic therapies, which target eosinophils or immunoglobulin E or the T-helper type 2 phenotype, especially in children, adolescents, and adults with frequent exacerbations. In children, a reduced forced expiratory volume in the first second of expiration (FEV1) to forced vital capacity ratio can be associated with future exacerbations, although the FEV1 may be in the normal range, even with children who have persistent severe asthma. Asthma control questionnaires did not differentiate between children with or children without a future exacerbation. Alternatively, in adults, the lower baseline FEV1 (2.3 L [74% predicted] versus 2.5 L [78% predicted]) identified patients more likely to have a future exacerbation compared with patients who were not having an exacerbation. After correcting for FEV1, the asthma control questionnaire data were associated with exacerbations. In adolescents (ages ≥ 12 years) and adults with persistent mild asthma, most (73%) did not have sputum eosinophilia, and some of these patients responded well to the anticholinergic, tiotropium, which would argue differently from administration of an inhaled corticosteroid as first-line controller therapy. In a three-track study of patients with persistent mild asthma, as-needed budesonide-formoterol and scheduled budesonide were associated with approximately one-half of the annual exacerbation rate of as-needed albuterol. In patients with persistent moderate-to-severe asthma, tiotropium added to controller therapy caused an increase in FEV1 without improving the asthma control questionnaire findings. There were two studies that explored whether either quadrupling or quintupling the inhaled corticosteroid at the first sign of loss of control of asthma would provide meaningful reductions of severe exacerbations of asthma, but the findings did not support this strategy. Both biologic therapies and environmental control (dust mite impermeable encasings) have resulted in reductions of exacerbations in patients with persistent moderate and severe asthma.

scholarly journals Montelukast as Add-On Therapy to Inhaled Corticosteroids in the Management of Asthma (the SAS trial)

2009 ◽  
Vol 16 (suppl a) ◽  
pp. 5A-10A ◽  
Author(s):  
J Mark Fitzgerald ◽  
Sylvain Foucart ◽  
Stephen Coyle ◽  
John Sampalis ◽  
Denis Haine ◽  
...  
Keyword(s):  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Inhaled Corticosteroid ◽  
Uncontrolled Asthma ◽  
Open Label ◽  
Asthma Control Questionnaire ◽  
Asthmatic Patients ◽  
The Mean ◽  
Clinically Significant ◽  
High Doses

AIM: To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy.DESIGN: An eight-week, multicentre, open-label, observational study.RESULTS: Of 320 patients enrolled, 288 (90.0%) completed the study. Of patients who had uncontrolled asthma symptoms (Canadian Asthma Consensus Guidelines Update, 2003) but were controlled according to the Asthma Control Questionnaire (ACQ score of less than 1.5), 93.9% maintained asthma control at week 8. Of patients with uncontrolled asthma at baseline for both definitions, 63.5% achieved asthma control by week 8. The mean ± SD ACQ score decreased from 1.13±0.28 to 0.57±0.50 (P<0.001) for controlled patients at baseline and from 2.38±0.73 to 1.03±0.80 (P<0.001) for patients who were uncontrolled at baseline, each representing a clinically significant improvement.CONCLUSION: Montelukast add-on therapy is an effective alternative to inhaled corticosteroid monotherapy.

scholarly journals Montelukast as Add-On Therapy to Inhaled Corticosteroids in the Management of Asthma (The SAS Trial)

2009 ◽  
Vol 16 (suppl a) ◽  
pp. 5A-10A ◽  
Author(s):  
J Mark FitzGerald ◽  
Sylvain Foucart ◽  
Stephen Coyle ◽  
John Sampalis ◽  
Denis Haine ◽  
...  
Keyword(s):  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Inhaled Corticosteroid ◽  
Uncontrolled Asthma ◽  
Open Label ◽  
Asthma Control Questionnaire ◽  
Asthmatic Patients ◽  
The Mean ◽  
Clinically Significant ◽  
High Doses

AIM: To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy.DESIGN: An eight-week, multicentre, open-label, observational study.RESULTS: Of 320 patients enrolled, 288 (90.0%) completed the study. Of patients who had uncontrolled asthma symptoms (Canadian Asthma Consensus Guidelines Update, 2003) but were controlled according to the Asthma Control Questionnaire (ACQ score of less than 1.5), 93.9% maintained asthma control at week 8. Of patients with uncontrolled asthma at baseline for both definitions, 63.5% achieved asthma control by week 8. The mean ± SD ACQ score decreased from 1.13±0.28 to 0.57±0.50 (P<0.001) for controlled patients at baseline and from 2.38±0.73 to 1.03±0.80 (P<0.001) for patients who were uncontrolled at baseline, each representing a clinically significant improvement.CONCLUSION: Montelukast add-on therapy is an effective alternative to inhaled corticosteroid monotherapy.

Cut-off points for defining asthma control in three versions of the Asthma Control Questionnaire

2010 ◽  
pp. 1-6
Author(s):  
Joaquin Sastre ◽  
Jose Olaguibel ◽  
Jose Maria Vega ◽  
Victoria Del Pozo ◽  
Cesar Picado ◽  
...  
Keyword(s):  
Asthma Control ◽  
Asthma Control Questionnaire

scholarly journals Higher Omega-3 Index Is Associated with Better Asthma Control and Lower Medication Dose: A Cross-Sectional Study

Nutrients ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 74 ◽  
Author(s):  
Isobel Stoodley ◽  
Manohar Garg ◽  
Hayley Scott ◽  
Lesley Macdonald-Wicks ◽  
Bronwyn Berthon ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Asthma Management ◽  
Airway Disease ◽  
Cross Sectional Study ◽  
Erythrocyte Membranes ◽  
Omega 3 ◽  
Asthma Control Questionnaire ◽  
Cross Sectional

Asthma is a chronic inflammatory airway disease, associated with systemic inflammation. Omega-3 polyunsaturated fatty acids (n-3 PUFA) have established anti-inflammatory effects, thus having potential as an adjunct therapy in asthma. This study aimed to compare erythrocyte n-3 PUFA in adults with (n = 255) and without (n = 137) asthma and determine the relationship between erythrocyte n-3 PUFA and clinical asthma outcomes. Subjects had blood collected, lung function measured and Juniper Asthma Control Questionnaire (ACQ) score calculated. Fatty acids were measured in erythrocyte membranes by gas chromatography, and the omega-3 index (O3I) was calculated (% eicosapentaenoic acid + % docosahexaenoic acid). O3I was similar in subjects with and without asthma (p = 0.089). A higher O3I was observed in subjects with controlled or partially controlled asthma (ACQ < 1.5) compared to subjects with uncontrolled asthma (ACQ ≥ 1.5) (6.0% (5.4–7.2) versus 5.6% (4.6–6.4) p = 0.033). Subjects with a high O3I (≥8%) had a lower maintenance dose of inhaled corticosteroids (ICS) compared to those with a low O3I (<8%) (1000 μg (400–1000) versus 1000 μg (500–2000) p = 0.019). This study demonstrates that a higher O3I is associated with better asthma control and with lower ICS dose, suggesting that a higher erythrocyte n-3 PUFA level may have a role in asthma management.

scholarly journals Use of the Asthma Control Questionnaire by the Asthma Clinical Research Network

2011 ◽  
Vol 38 (5) ◽  
pp. 1242-1242
Author(s):  
M. J. Walter ◽  
M. Castro ◽  
E. Israel ◽  
C. A. Sorkness ◽  
Keyword(s):  
Clinical Research ◽  
Asthma Control ◽  
Research Network ◽  
Asthma Control Questionnaire ◽  
Clinical Research Network

scholarly journals Body Mass Index and Comorbidities in Adult Severe Asthmatics

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Andreina Bruno ◽  
Elisabetta Pace ◽  
Fabio Cibella ◽  
Pascal Chanez
Keyword(s):  
Asthma Control ◽  
Severe Asthma ◽  
Type Ii Diabetes ◽  
Cross Sectional Study ◽  
Poor Quality ◽  
Normal Weight ◽  
Type Ii ◽  
Asthma Control Questionnaire ◽  
Cross Sectional ◽  
Oral Corticosteroids

Both severe asthma and obesity are growing health problems. Severe asthma leads to a poor quality of life. The relationship among BMI, comorbidities, and severe asthma control in adults is still unclear. The aim of the study is to better understand the effect of the comorbidities as atopy, type II diabetes, OSAS, gastroesophageal reflux, hypertension, cardiovascular diseases, osteoporosis, infections, and psychological factors with BMI on asthma control in a cohort of adult severe asthmatics. One hundred and two patients were enrolled in a cross-sectional study assessing asthma control, treatments, pulmonary function, inflammatory markers, and comorbidities. Patients were divided into 3 classes according to BMI: normal weight, overweight, and obese. We found that the optimal state of asthma control is lower. whereas the score of Asthma Control Questionnaire, the number of asthma exacerbations during last year, the oral corticosteroids requirement during the previous year, and the LABA treatments are higher in obese than in overweight and normal weight severe asthmatics. The number of subjects with type II diabetes and OSAS are higher among obese and overweight patients than in normal weight asthmatics. In conclusion, BMI representsper sea factor for the deterioration in disease control in severe asthma.

scholarly journals Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Michael J. McGeachie ◽  
Joanne E. Sordillo ◽  
Amber Dahlin ◽  
Alberta L. Wang ◽  
Sharon M. Lutz ◽  
...  
Keyword(s):  
Asthma Control ◽  
Corticosteroid Therapy ◽  
Inhaled Corticosteroid
Sign in / Sign up

Export Citation Format

Share Document